Suchergebnisse - "Clinical Trial, Phase III"

PubPharm (18.819)

31

Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis : Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)

enthalten in: Journal of the European Academy of Dermatology and Venereology : JEADV | 2024

von Strober, B. | Bachelez, H. | Crowley, J. | +9

32

Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women Using the Dapivirine Vaginal Ring

enthalten in: The Journal of infectious diseases | 2024

von Stalter, R. | Dong, T. | Hendrix, C. | +30

33

Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis : a post hoc analysis of a phase 3b/4 randomised safety study

enthalten in: RMD open | 2024

von Buch, M. | Bhatt, D. | Charles-Schoeman, C. | +10

34

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer

enthalten in: The New England journal of medicine | 2024

von Wu, Y. | Dziadziuszko, R. | Ahn, J. | +120

35

Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia : a randomized phase 3 trial with 5-year outcomes

enthalten in: Journal of cancer research and clinical oncology | 2024

von Tian, J. | Song, Y. | Zhang, G. | +24

36

Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Park, S. | Kim, T. | Han, J. | +21

37

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma : Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Motzer, R. | Porta, C. | Eto, M. | +134

38

Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors : Final Results of CheckMate 722

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Mok, T. | Nakagawa, K. | Park, K. | +20

39

Patient-Reported Outcomes in OlympiA : A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Ganz, P. | Bandos, H. | Španić, T. | +43

40

Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains : results from two phase 3 randomised studies, BE MOBILE 1 and 2

enthalten in: RMD open | 2024

von Navarro-Compán, V. | Ramiro, S. | Deodhar, A. | +9